UroGen Pharma (NASDAQ:URGN) Trading 3.6% Higher – What’s Next?

UroGen Pharma Ltd. (NASDAQ:URGN) shot up 3.6% during trading on Thursday . The company traded as high as $12.06 and last traded at $12.09. 285,917 shares were traded during trading, a decline of 43% from the average session volume of 497,520 shares. The stock had previously closed at $11.66.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on URGN shares. D. Boral Capital restated a “buy” rating and issued a $25.00 target price on shares of UroGen Pharma in a report on Monday, March 10th. HC Wainwright reduced their price objective on shares of UroGen Pharma from $64.00 to $55.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. Finally, LADENBURG THALM/SH SH began coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They issued a “buy” rating and a $31.00 target price on the stock. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, UroGen Pharma currently has an average rating of “Buy” and a consensus price target of $38.20.

UroGen Pharma Trading Up 0.9 %

The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The company’s 50 day moving average is $10.54 and its 200 day moving average is $11.59. The stock has a market capitalization of $559.12 million, a price-to-earnings ratio of -3.85 and a beta of 1.12.

UroGen Pharma (NASDAQ:URGN) last released its earnings results on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The company had revenue of $24.57 million for the quarter, compared to analyst estimates of $25.25 million. On average, research analysts forecast that UroGen Pharma Ltd. will post -3.12 EPS for the current fiscal year.

Insider Transactions at UroGen Pharma

In related news, insider Mark Schoenberg sold 4,551 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now owns 145,666 shares of the company’s stock, valued at $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the transaction, the general counsel now owns 26,468 shares of the company’s stock, valued at approximately $294,853.52. This represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is owned by insiders.

Institutional Trading of UroGen Pharma

A number of large investors have recently bought and sold shares of the stock. RTW Investments LP boosted its stake in shares of UroGen Pharma by 1.3% in the 4th quarter. RTW Investments LP now owns 3,834,794 shares of the company’s stock valued at $40,841,000 after purchasing an additional 47,447 shares in the last quarter. Toronto Dominion Bank bought a new position in UroGen Pharma during the 4th quarter valued at about $18,628,000. Vestal Point Capital LP boosted its position in UroGen Pharma by 307.5% in the fourth quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company’s stock valued at $17,360,000 after buying an additional 1,230,000 shares in the last quarter. Acorn Capital Advisors LLC bought a new stake in UroGen Pharma during the fourth quarter worth about $16,149,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of UroGen Pharma by 2.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,377,156 shares of the company’s stock worth $14,667,000 after buying an additional 36,084 shares in the last quarter. 91.29% of the stock is currently owned by institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.